A review of selected systemic antifungal drugs for use in dogs and cats - Veterinary Medicine
Medicine Center
DVM Veterinary Medicine Featuring Information from:


A review of selected systemic antifungal drugs for use in dogs and cats
This pharmacologist reviews a few of your antifungal choices, specifically the azoles andterbinafine. These drugs have a broad spectrum of activity—with some important differences.


10. Ward KW, Stelman GJ, Morgan JA, et al. Development of an in vivo preclinical screen model to estimate absorption and first-pass hepatic extraction of xenobiotics. II. Use of ketoconazole to identify P-glycoprotein/CYP3A-limited bioavailability in the monkey. Drug Metab Dispos 2004;32(2):172-177.

11. Mealey KL. Therapeutic implications of the MDR-1 gene. J Vet Pharmacol Ther 2004;27(5):257-264.

12. Myre SA, Schoeder TJ, Grund VR, et al. Critical ketoconazole dosage range for ciclosporin clearance inhibition in the dog. Pharmacology 1991;43(5):233-241.

13. McAnulty JF, Lensmeyer GL. The effects of ketoconazole on the pharmacokinetics of cyclosporine A in cats. Vet Surg 1999;28(6):448-455.

14. Menegola E, Broccia ML, Di Renzo F, et al. Dysmorphogenic effects of some fungicides derived from the imidazole on rat embryos cultured in vitro. Reprod Toxicol 2006;21(1):74-82.

15. Willard MD, Nachreiner RF, Howard VC, et al. Effect of long-term administration of ketoconazole in cats. Am J Vet Res 1986;47(12):2510-2513.

16. Bennet JE. Antimicrobial agents: antifungal agents. In: Brunton LL, Lazo JS, Parker KL, eds. Goodman & Gilman's pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill, 2005;1225-1241.

17. Berman J. Clinical status of agents being developed for leishmaniasis. Expert Opin Investig Drugs 2005;14(11):1337-1346.

18. Kohler LM, Monteiro PC, Hahn RC, et al. In vitro susceptibilities of isolates of Sporothrix schenckii to itraconazole and terbinafine. J Clin Microbiol 2004;42(9):4319-4320.

19. Chapman SW, Pappas P, Kauffmann C, et al. Comparative evaluation of the efficacy and safety of two doses of terbinafine (500 and 1000 mg day(-1)) in the treatment of cutaneous or lymphocutaneous sporotrichosis. Mycoses 2004;47(1-2):62-68.

20. Van Cauteren H, Heykants J, De Coster R, et al. Itraconazole: pharmacologic studies in animals and humans. Rev Infect Dis 1987;9(suppl 1):S43-S46.

21. Boothe DM, Herring I, Calvin J, et al. Itraconazole disposition after single oral and intravenous and multiple oral dosing in healthy cats. Am J Vet Res 1997;58(8):872-877.

22. Pinchbeck LR, Hillier A, Kowalski JJ, et al. Comparison of pulse administration versus once daily administration of itraconazole for the treatment of Malassezia pachydermatis dermatitis and otitis in dogs. J Am Vet Med Assoc 2002;220(12):1807-1812.

23. Legendre AM, Rohrbach BW, Toal RL, et al. Treatment of blastomycosis with itraconazole in 112 dogs. J Vet Intern Med 1996;10(6):365-371.

24. Queiroz-Telles F, Purim KS, Boguszewski CL, et al. Adrenal response to corticotrophin and testosterone during long-term therapy with itraconazole in patients with chromoblastomycosis. J Antimicrob Chemother 1997;40(6):899-902.

25. Lavrijsen K, van Houdt J, Thijs D, et al. Interaction of miconazole, ketoconazole and itraconazole with rat-liver microsomes. Xenobiotica 1987;17(1):45-57.


Click here